<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477711</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62202-769</org_study_id>
    <nct_id>NCT00477711</nct_id>
  </id_info>
  <brief_title>A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer</brief_title>
  <acronym>EXTRA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and
      capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer remains one of the major causes of cancer deaths around the world, especially
      in Asia. Previous study of ML17032 has proved that XP(capecitabine plus cisplatin)is
      effective in advanced gastric cancer, with the overall response rate of 41%, the median PFS
      of 5.6 month. Recently, the EGFR monoclonal antibody of cetuximab has shown to be successful
      in treating advanced colorectal cancer with or without chemotherapy. Since EGFR also express
      in gastric cancer, A single arm, open, multicenter phase II study of cetuximab in combination
      with cisplatin and capecitabine as first line treatment in patient with advanced gastric
      cancer.If applicable, the value of mutations in k-ras, b-raf, P53, and EGFR copy number to
      predict the clinical response to cetuximab in advanced gastric cancer patients will also be
      accessed.Tumor tissue from study patients will be checked for k-ras, b-raf, and P53 mutation
      by sequencing and for EGFR copy number by chromogenic in situ hybridization. DNA will be
      extracted from paraffin-embedded samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>C225+Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab, cisplatin, capecitabine</intervention_name>
    <description>Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously</description>
    <arm_group_label>C225+Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed informed consent

          -  Age 18 to 75 years old

          -  Histologically confirmed gastric adenocarcinoma

          -  Unresectable recurrent or metastatic disease

          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more
             than 12 months

          -  Measurable disease according to the RECIST criteria

          -  Karnofsky performance status ≥60

          -  Life expectancy of ≥2 month

          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than
             4 weeks

          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)

          -  Serum albumin level ≥3.0g/dL

          -  Serum AKP &lt; 2.5 times ULN

          -  Serum creatinine &lt;1.5mg/dL

          -  Bilirubin level &lt; 1.5mg/dL

          -  Serum creatinine &lt;1.5 times ULN

          -  WBC&gt;3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl

        Exclusion Criteria:

          -  Brain metastasis (known or suspected)

          -  Previous systemic therapy for metastatic gastric cancer

          -  Inability to take oral medication

          -  Previous EGFR pathway-targeting therapy

          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry

          -  Heart failure, coronary artery disease, myocardial infarction within the last 6 months

          -  Known allergy to any study treatment

          -  Pregnancy or lactation period

          -  Any investigational agent within the past 28 days

          -  Other previous malignancy within 5 year, except non-melanoma skin cancer

          -  Previous adjuvant therapy with capecitabine+platinum

          -  Pre-existing neuropathy&gt;grade 1

          -  Legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University, School of oncology, Gastrointestinal Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University,School of Oncology, Gastrointestinal Department</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>pro.</investigator_title>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>cisplatin</keyword>
  <keyword>capecitabine</keyword>
  <keyword>first line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

